The stock of Eli Lilly and Company (NYSE:LLY) increased by increased by $2.58 on Friday to finish at $243.75, up 1.07 percent. The last five days have seen an average of 1,867,100 shares of common stock traded. 21 times new highs were reached in the current year, with a gain of $74.91. The average number of shares traded over the last 20 days was 2,521,665, while the average volume over the last 50 days totaled 2,516,762.
LLY stock appreciated 4.98% since last month. On 09/28/21, the company’s shares reached a one-month low of $220.20. The stock touched a high of $275.87 on 08/17/21, after rallying from a low of $129.21 in 52 weeks. The price of LLY stock has risen by 44.37% or $74.91 this year, reaching a new high 21 times. Still, the stock price is down -11.64% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
There have been 68 days since Eli Lilly and Company (LLY) last reported insider trading activity on Aug 18. On Aug 18, 10% Owner LILLY ENDOWMENT INC sold 15,430 shares at $274.31 each. This transaction resulted in the insider making $4,232,603. On Aug 17, LILLY ENDOWMENT INC sold 3,060 shares at a price of US$274.08. After the transaction, the insider now owns 108,264,040 shares. 10% Owner LILLY ENDOWMENT INC had earlier sold 104,711 shares on Aug 09 for $267.50 a share. The transaction was completed for $28,010,135.
Eli Lilly and Company (LLY) has a trailing price-to-earnings (P/E) ratio of 36.64. This level actually compares unfavorably with the industry at large, as the PE for the Drug Manufacturers – General industry stands at about 27.25. Further, its PE also compares unfavorably with the Healthcare sector’s trailing 12 months PE ratio, which comes in at 33.43 right now. The PE ratio of Eli Lilly and Company has varied between 263.64 and 13.06 in the last five years. Beta for the stock is 0.29. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 8.63, the price-to-book (PB) ratio of 34.33, and the price-to-cash flow ratio of 86.06.
Eli Lilly and Company’s dividend is $3.40 per share per year. With a dividend yield of 1.39%, LLY has a payout ratio of 47.60%. Company paid $0.85 per share in dividends, remained unchanged from $0.85 last year. A $0.11 dividend increase was reported on Monday December 14 2020, making it the 7 consecutive year the dividend has increased. Over the last three years, dividends have increased by 42.31%.
For the three months ended June 29, Eli Lilly and Company’s quick ratio was 0.90, while its current ratio was 1.10, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 2.29, and the total debt to equity ratio is 2.56. As far as profitability goes, gross margin for the trailing twelve months is 74.30% percent. Eli Lilly and Company’s EBITDA margin for the year ended June 29 was 33.31%, whereas its operating margin stood at 21.80% for the same period. Based on annual data, it had gross profit of $19.06 billion and revenue of $24.54 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. LLY’s return on assets (ROA) during the last 12 months has been 13.10%. There was a 22.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 102.00%. ROE has averaged -15.50 in the past year for the broader industry.
According to Eli Lilly and Company’s quarterly financial report for the quarter that ended June 29, it had $14.74 billion in total debt versus $51.2 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $6.74 billion, while revenues rose by 18.41% to $6.81 billion. It was predicted that Eli Lilly and Company’s quarterly earnings would be $1.87, but it ended up being $1.89, beating the consensus by -1.10%. EBITDA was $1.77 billion for the quarter. At the end of Eli Lilly and Company’s most recent quarter ended June 29, its liabilities totaled 41.15 billion, while its total debt was $16.3 billion. Equity owned by shareholders amounts to $956.58 million.
Here’s a quick look at Eli Lilly and Company’s (LLY) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 66.24%, suggesting the stock is Neutral, with a 11.88% historical volatility rate.
The stochastic %K and %D were 85.77% and 87.96% respectively, while the average true range (ATR) was 4.82. Based on the 14-day stochastic reading of 89.17%, the RSI (14) reading is 59.15%. On the 9-day MACD Oscillator, the stock is at 3.58, and the 14-day reading is at 6.22.
In its most recent analyst report, Berenberg raised its rating on Eli Lilly and Company (NYSE: LLY) to a Buy. Prior to this, analysts firm rated the stock as a Hold. Analysts have assigned Eli Lilly and Company (LLY) an Overweight rating. LLY is a stock that is recommended for selling by 0 brokerage firms, while 4 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 2 rates it overweight and 10 others recommend it as a buy.
What is LLY’s price target for the next 12 months?
The current consensus forecast for the stock is between $230.00 and $315.00, with a median target price of $279.00. In analyzing these forecasts, the average price target given by analysts for Eli Lilly and Company (LLY) is $276.40.